- Trials with a EudraCT protocol (253)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
253 result(s) found for: Fusion Protein.
Displaying page 1 of 13.
EudraCT Number: 2021-001367-24 | Sponsor Protocol Number: 217043 | Start Date*: 2021-11-16 | |||||||||||
Sponsor Name:GlaxoSmithKline SA | |||||||||||||
Full Title: A Phase II, randomized, partially blinded study to assess the safety, tolerability and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants. | |||||||||||||
Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) DE (Trial now transitioned) PL (Trial now transitioned) IT (Temporarily Halted) FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012672-27 | Sponsor Protocol Number: CIP0702PLF/EU | Start Date*: 2009-08-17 | |||||||||||
Sponsor Name:ApaTech Limited | |||||||||||||
Full Title: "A prospective, randomised study comparing the use of Actifuse™ ABX synthetic bone substitute with INFUSE® in patients requiring posterolateral instrumented lumbar fusion with interbody fusion" als... | |||||||||||||
Medical condition: Prospective trial participants will have been diagnosed with degenerative disc disease with a treatment option of decompression and Interbody Fusion with Posterolateral Intertransverse Process Fusi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000769-18 | Sponsor Protocol Number: EFC16295 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bioverativ Therapeutics Inc. | |||||||||||||
Full Title: A Phase 3 open-label, multicenter study of the safety, efficacy, and pharmacokinetics of intravenous recombinant coagulation Factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-X... | |||||||||||||
Medical condition: Hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) IE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) HU (Completed) NL (Completed) IT (Ongoing) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002215-22 | Sponsor Protocol Number: LTS16294 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Bioverativ Therapeutics Inc. | |||||||||||||
Full Title: A Phase 3 open-label, multicenter study of the long-term safety and efficacy of intravenous recombinant coagulation factor VIII Fc-von willebrand factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; BIVV... | |||||||||||||
Medical condition: Hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) FR (Ongoing) GR (Ongoing) IE (Trial now transitioned) SE (Trial now transitioned) HU (Ongoing) DE (Trial now transitioned) BG (Trial now transitioned) IT (Ongoing) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002023-15 | Sponsor Protocol Number: EFC16293 | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:Bioverativ Therapeutics Inc. (a Sanofi company) | |||||||||||||
Full Title: Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTE... | |||||||||||||
Medical condition: severe hemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) BG (Completed) BE (Completed) GR (Completed) HU (Completed) NL (Completed) ES (Completed) Outside EU/EEA IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000675-34 | Sponsor Protocol Number: EU 101 | Start Date*: 2004-12-21 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: A Prospective, Randomized, Controlled, Multi-center, (Pilot) Study of Osigraft® in Instrumented Posterolateral Fusions | ||
Medical condition: Subjects qualifying for decompression and fusion of one spinal level (L3-S1) with the use of autograft will be recruited through the medical institutions of participating investigators. All subject... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002096-29 | Sponsor Protocol Number: iVRCT | Start Date*: 2015-07-20 | ||||||||||||||||
Sponsor Name:Speising Orthopaedic Hospital Vienna | ||||||||||||||||||
Full Title: Application of Intrawound Vancomycin Powder in Spinal Fusion Surgery to Reduce Postoperative Surgical Site Infections - A Prospective Randomized Controlled Trial | ||||||||||||||||||
Medical condition: Postoperative surgical site infections (deep and superficial) after spinal fusion surgery | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000860-14 | Sponsor Protocol Number: GR-OG-279239-03 | Start Date*: 2018-02-27 | |||||||||||
Sponsor Name:Genera Research Ltd | |||||||||||||
Full Title: Patient and evaluator blinded non-inferiority study on safety, tolerability and lumbar fusion efficacy of a single administration of Osteogrow (rhBMP6 in autologous blood coagulum (ABC) carrier) in... | |||||||||||||
Medical condition: Lumbar spine single segment destabilization caused by degenerative disc disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004741-37 | Sponsor Protocol Number: 212458 | Start Date*: 2021-06-21 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase I/II, randomised, controlled study to assess the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine when administered to healthy adults (Phase I) and to healt... | ||
Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) FI (Completed) Outside EU/EEA PL (Ongoing) SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002716-16 | Sponsor Protocol Number: PH-L19IL2-01/05 | Start Date*: 2005-11-04 | |||||||||||
Sponsor Name:PHILOGEN S.P.A. | |||||||||||||
Full Title: A DOSE FINDING PHARMACOKINETIC STUDY OF THE TUMOUR TARGETING HUMAN L19IL2 MONOCLONAL ANTIBODY CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED SOLID TUMOURS | |||||||||||||
Medical condition: solid tumors and renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000979-27 | Sponsor Protocol Number: V102_16 | Start Date*: 2015-05-07 |
Sponsor Name:Novartis Vaccines and Diagnostics | ||
Full Title: A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolesc... | ||
Medical condition: Prophylaxis against invasive disease strains of N. meningitidis serogroup B. | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-001670-33 | Sponsor Protocol Number: 215344 | Start Date*: 2022-02-07 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents | |||||||||||||
Medical condition: Healthy volunteers (Active immunization against IMD caused by N.meningitidis serogroups A, B, C, W and Y) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000640-18 | Sponsor Protocol Number: NANT2015-02 | Start Date*: 2018-08-13 |
Sponsor Name:NANT Operations Centre | ||
Full Title: NANT 2015-02: PHASE 1 STUDY OF LORLATANIB (PF-06463922), AN ORAL SMALL MOLECULE INHIBITOR OF ALK/ROS1, FOR PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA | ||
Medical condition: Relapsed or refractory high risk neuroblastoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005489-37 | Sponsor Protocol Number: CSL654_3003 | Start Date*: 2014-07-11 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B | |||||||||||||
Medical condition: Hemophilia B | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) CZ (Completed) BG (Completed) ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002451-15 | Sponsor Protocol Number: V102_15 | Start Date*: 2014-09-19 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals SA | |||||||||||||
Full Title: A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK... | |||||||||||||
Medical condition: The current study is designed to assess immunological non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to healthy adolescents 10 to 18 years of age, to those o... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002230-69 | Sponsor Protocol Number: V102_15E1 | Start Date*: 2016-10-31 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals S.A. | |||||||||||||
Full Title: A Phase 2b, Open-Label, Multi-Center Study Assessing the Immunological Persistence of Antibodies at Approximately 2 years After the last Meningococcal Vaccination in Study V102_15 and the Response ... | |||||||||||||
Medical condition: Meningococcal diseases | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006032-23 | Sponsor Protocol Number: CSL654_3002 | Start Date*: 2012-07-20 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: A Phase III Open-label, Multicenter, Pharmacokinetics, Safety, and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Children ... | |||||||||||||
Medical condition: Prophylaxis and treatment of bleeding episodes in previously treated children with congenital FIX deficiency (hemophilia B) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018477-38 | Sponsor Protocol Number: CSL654_2001 | Start Date*: 2010-11-15 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: An Open-label, Multicenter, Dose-Escalation Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B. | |||||||||||||
Medical condition: Prophylaxis and treatment of bleeding episodes in subjects with congenital Factor IX (FIX) deficiency (Hemophilia B) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) ES (Completed) GB (Completed) IT (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003937-41 | Sponsor Protocol Number: V102_03E1 | Start Date*: 2014-01-17 | |||||||||||
Sponsor Name:GSK Vaccines S.r.l | |||||||||||||
Full Title: Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Follow... | |||||||||||||
Medical condition: This study will evaluate the safety and immunogenicity of a booster dose of MenABCWY vaccine; either MenABCWY+OMV or MenABCWY+1/4OMV, administered to adolescent and young adults who previously rece... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003822-42 | Sponsor Protocol Number: B1971048 | Start Date*: 2015-01-30 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A Phase 4, Single-Arm, Open-Label Study describing the safety and immunogenicity of Bexsero in healthy subjects aged 12 years to <19 years. | |||||||||||||
Medical condition: Test the safety and immunogenicity of Bexsero used as a vaccine for Neisseria meningitidis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.